secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001213900-25-001392
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix reports preliminary Q4 2024 net revenue ~$31M, FY ~$43M; Q4 Adj EBITDA >$12M
--------------------------------------------------------------------------------

- Q4 2024 prelim unaudited net revenue ~$31M; FY 2024 ~$43M; Q4 Adj EBITDA >$12M.
- Open purchase orders >$25M for Q1 2025 delivery; shipping DefenCath to all three MDO customers.
- LDO implementation targeted H1 2025; aims for 4,000 patients in H2 2025.
- Expanded inpatient deployment with Syneos Health in Q1 2025; field team reorganized, some roles eliminated.
- FY 2025 opex guidance $72-78M (excl non-cash/one-time); cash & investments ~$52M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/0001213900-25-001392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/ea0226957-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-001392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer